The scientific achievements of the decades in Korean Acute Myocardial Infarction Registry

Kim, Hyun Kuk; Jeong, Myung Ho; Lee, Seung Hun; Sim, Doo Sun; Hong, Young Joon; Kim, Chong Jin; Cho, Myeong Chan; Kim, Young Jo

doi:10.3904/kjim.2014.29.6.703

Cited by 19 publications

(17 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both registries are prospective multicentre online Korean registries reflecting current practice in the management and clinical outcomes of Asian patients diagnosed with AMI. The protocols and details of the registry have been previously published 10 11. Data were collected at each site by an experienced study coordinator using a standardised case report form and protocol, and then merged with the intention of improving the statistical power.…”

Section: Methodsmentioning

confidence: 99%

Gender differences in risk factors and clinical outcomes in young patients with acute myocardial infarction

Cho

Shin

Ann

et al. 2016

J Epidemiol Community Health

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Gender differences in risk factors and clinical outcomes in young patients with acute myocardial infarction

Cho

Shin

Ann

et al. 2016

J Epidemiol Community Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…KAMIR is the first nationwide, multicenter data-collection registry in Korea, designed to capture the outcomes of patients with acute myocardial infarction (MI). 6 We identified 9759 patients (≥18 years) with STEMI (<12 hours) eligible for either fibrinolysis or PPCI. All fibrinolysis procedures were performed in the in-hospital setting, and of 881 patients receiving fibrinolysis, 843 patients (96%) underwent coronary angiography and 726 patients underwent (82%) subsequent PCI.…”

mentioning

confidence: 99%

Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment–Elevation Myocardial Infarction

Sim

Jeong

Ahn

et al. 2016

Circ: Cardiovascular Interventions

Self Cite

View full text Add to dashboard Cite

P rimary percutaneous coronary intervention (PPCI) is the preferred reperfusion therapy for most patients with ST-segment-elevation myocardial infarction (STEMI).1 However, many patients fail to receive timely PPCI because of geographical or logistical issues. In such cases, pharmacoinvasive strategy where fibrinolysis is followed by immediate Background-The Strategic Reperfusion Early After Myocardial Infarction trial and the French Registry of Acute STelevation or Non-ST-elevation Myocardial Infarction 2015 suggested that pharmacoinvasive strategy compares favorably with primary percutaneous coronary intervention (PPCI). We sought to assess the clinical impact of pharmacoinvasive strategy compared with PPCI in real-world patients with ST-segment-elevation myocardial infarction. Methods and Results-We used the Korea Acute Myocardial Infarction Registry to identify ST-segment-elevation myocardial infarction patients receiving either pharmacoinvasive strategy defined as fibrinolysis followed by percutaneous coronary intervention (rescue/urgent or routine elective; n=708) or PPCI (n=8878). Patients receiving facilitated percutaneous coronary intervention within 3 hours from fibrinolysis were excluded. Propensity-matched 12-month clinical outcome was compared. In the propensity-matched cohort (n=706 in each group), the pharmacoinvasive group had shorter time to reperfusion therapy (165 versus 241 minutes; P<0.001) and higher rate of pre-percutaneous coronary intervention Thrombolysis in Myocardial Infarction grade 3 (50.4% versus 13.7%; P<0.001). Incidences of major bleeding and stroke during hospitalization were not different. Twelve-month rates of death and major adverse cardiac events (composite of death, recurrent myocardial infarction, target-vessel revascularization, and coronary artery bypass graft surgery) were similar between pharmacoinvasive strategy and PPCI: 4.4% versus 4.1% and 7.5% versus 7.8%, respectively. Equipoise between pharmacoinvasive strategy and PPCI for 12-month major adverse cardiac events occurred when percutaneous coronary intervention-related delay was ≈100 minutes. Conclusions-ST-segment-elevation myocardial infarction patients receiving pharmacoinvasive treatment, compared with PPCI, had shorter time to reperfusion, higher culprit-vessel patency, and similar 12-month clinical outcome. In contrast, facilitated PCI consisting of fibrinolysis followed by immediate planned PCI is not recommended because of increased risk of death, intracranial hemorrhage, and ischemic events. 4,5 There are currently few large-scale studies that provide data regarding the efficacy of pharmacoinvasive strategy compared with PPCI in real-world STEMI patients. In the present study, we sought to evaluate the 12-month clinical outcome of patients with STEMI undergoing pharmacoinvasive strategy compared with PPCI using KAMIR (Korea Acute Myocardial Infarction Registry). Methods Study Population and Data CollectionThe study population was derived from KAMIR between November 2005 and December 2011. KAMIR is the fi...

show abstract

“…At the same time, improving the quality of care is also required through long-term monitoring and an adequate registry system. 22) …”

Section: Discussionmentioning

confidence: 99%

Thirty-Year Trends in Mortality from Cardiovascular Diseases in Korea

et al. 2015

View full text Add to dashboard Cite

Background and ObjectivesAn understanding of cardiovascular diseases (CVD) mortality is important for the development of strategies aimed at reducing the burden of CVD. Thus, we examined the changing pattern of CVD mortality in Korea over 30 years (1983-2012) by analyzing the Cause of Death Statistics.Materials and MethodsDeaths from diseases of the circulatory system and those of five CVD categories were analyzed: total heart diseases, acute rheumatic fever/chronic rheumatic heart disease, hypertensive heart disease, ischemic heart disease (IHD) and atherosclerosis. To assess the effects of population ageing on CVD mortality, crude and age-adjusted mortality rates were calculated. Age-adjusted mortality rates were calculated by using the direct standardization method.ResultsOver the 30-year period analyzed in this study, circulatory system disease mortality markedly declined. The age-adjusted mortality rate decreased by 78.5% in men and by 76.3% in women. Consistent decreasing trends were observed for mortalities from rheumatic heart disease, hypertensive heart disease, and atherosclerosis. However, IHD mortality rapidly increased during the 30 years. Crude IHD mortality showed a steady increase until 2007, after which there were fluctuations. But the penalized regression splines showed that crude IHD mortality continued to increase. Age-adjusted IHD mortality peaked in the early 2000s, and started to decrease during the last few years.ConclusionIn summary, total CVD mortality rate has significantly decreased over the 30-year period analyzed in this study but the IHD mortality rate has continuously increased until recently. The prevention and management of cardiovascular diseases amongst the Korean population, especially IHD, still represents a great challenge.

show abstract

The scientific achievements of the decades in Korean Acute Myocardial Infarction Registry

Cited by 19 publications

References 89 publications

Gender differences in risk factors and clinical outcomes in young patients with acute myocardial infarction

Gender differences in risk factors and clinical outcomes in young patients with acute myocardial infarction

Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment–Elevation Myocardial Infarction

Thirty-Year Trends in Mortality from Cardiovascular Diseases in Korea

Contact Info

Product

Resources

About